
DIAGAST MILESTONES

1968 - THE VERY BEGINNING
Sale of polyclonal sera for blood grouping.

1984 - INNOVATION BECAME A TRUE "TRADEMARK
Start of production of monoclonal antibodies in fermentors at the Lille's Regional Transfusion Center.

1988 - DIAGAST IS HENCEFORTH A STANDALONE COMPANY
Creation of DIAGAST with the industrial production of monoclonal antibodies.

1997 - FIRST STEP IN CERTIFICATION
ISO 9001-1994 Certification.

2003 - STRONG COMMITMENT TO QUALITY ASSURANCE SINCE 1997
ISO 9001:2000, ISO 13485:2001 and EC Marking.

2004 - MAGNETIC ATTRACTION OF A BRAND NEW TECHNOLOGY
Launch of EM®Technology, a new technology based on the RBC's magnetization.

2005 - CREATION OF A SUBSIDIARY IN SPAIN
DIAGAST Iberica is born.

2008 - ON THE ROAD TO NEW MARKETS IN NORTH AMERICA
FDA approval received in the USA and supply of reagents used in American blood banks.

2009 - QWALYS® 3: A NEW ERA OF ABSOLUTE PERFORMANCE
Third generation of QWALYS®.

2010 - DIAGAST IS BRANCHING OUT INTO THE ASIAN MARKETS
Subsidiary opened in India: DIAGAST India.

2012 - M-TRAP®: A COMPLETE BREAKTHROUGH VS THE EXISTING TECHNOLOGIES
Launch of M-TRAP®, a new technology for determining blood groups, and a new bedside card ABTest Card®.

2014 - FIRST STRATEGIC ACQUISITION FOR DIAGAST
Takeover of the start-up ABODiag and acquisition of new patents.

2016 - LAUNCH OF ABD PAD®
An innovative IVDMD for the confirmation of manual blood group, in 3 steps and 30 seconds.

2017 - QWALYS 3® EVO WHEN QWALYS® IS REINVENTING ITSELF
A STAT function, a dynamic scheduler and a new user interface: 3 news features that make the difference.

2019 - NEW INDUSTRIAL PREMISES
It doubles our production capacities and provides an industrial resource offering the highest levels of performance